Company

NEUROLMED Co., Ltd.

NEUROLMED develops drugs and AI tools for central nervous system diseases.

About

NEUROLMED develops drugs from biomolecules and natural products for chronic degenerative brain disorders, including stroke, Parkinson's disease, and Alzheimer's disease. Its pipeline includes NRM-331, NRM-205, NRM-021, and NRM-803, and it also develops an AI platform for brain science. Founded in 2019, the company is based in Gyeonggi-do, South Korea, and raised seed funding from KB Investment in February 2022.

3Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in